TET1 and acute lymphoblastic leukemia: Based on the evidence that PARP-1 can impact the activity of the TET1 enzyme at the transcriptional and enzymatic levels [39,48,49], the use of the PARPi olaparib was effective in antagonising leukaemic growth of T-ALL, negatively impacting TET1 expression and 5hmC marks [83].